Publications

  1. Hieken TJ, Chen J, Chen B, Johnson S, Hoskin TL, Degnim AC, Walther-Antonio MR, Chia N. The breast tissue microbiome, stroma, immune cells and breast cancer. Neoplasia. 2022 May; 27:100786 Epub 2022 Mar 30
    View PubMed
  2. Sideras K, Hillman DW, Giridhar K, Ginos BF, Tenglin RC, Liu H, Chen B, Tan W, Gross GG, Mowat RB, Dueck AC, Perez EA, Moreno-Aspitia A. Randomized Phase II Study of Two Doses of Pixantrone in Patients with Metastatic Breast Cancer (NCCTG N1031, Alliance). Oncologist. 2022 Apr 21 [Epub ahead of print]
    View PubMed
  3. Erickson LA, Chen B. Desmoid Tumor and Multiple Colon Adenomas. Mayo Clin Proc. 2022 Jan; 97 (1):193-195
    View PubMed
  4. Symmans WF, Yau C, Chen YY, Balassanian R, Klein ME, Pusztai L, Nanda R, Parker BA, Datnow B, Krings G, Wei S, Feldman MD, Duan X, Chen B, Sattar H, Khazai L, Zeck JC, Sams S, Mhawech-Fauceglia P, Rendi M, Sahoo S, Ocal IT, Fan F, LeBeau LG, Vinh T, Troxell ML, Chien AJ, Wallace AM, Forero-Torres A, Ellis E, Albain KS, Murthy RK, Boughey JC, Liu MC, Haley BB, Elias AD, Clark AS, Kemmer K, Isaacs C, Lang JE, Han HS, Edmiston K, Viscusi RK, Northfelt DW, Khan QJ, Leyland-Jones B, Venters SJ, Shad S, Matthews JB, Asare SM, Buxton M, Asare AL, Rugo HS, Schwab RB, Helsten T, Hylton NM, van 't Veer L, Perlmutter J, DeMichele AM, Yee D, Berry DA, Esserman LJ. Assessment of Residual Cancer Burden and Event-Free Survival in Neoadjuvant Treatment for High-risk Breast Cancer: An Analysis of Data From the I-SPY2 Randomized Clinical Trial. JAMA Oncol. 2021 Nov 1; 7 (11):1654-1663
    View PubMed
  5. Geiersbach KB, Sill DR, Del Rosario KM, Meyer RG, Spears GM, Yuhas JA, Sukov WR, Jenkins RB, Ocal IT, Mounajjed T, Chen B. Detailed Reanalysis of 500 Breast Cancers With Equivocal HER2 Immunohistochemistry and Borderline ERBB2 Fluorescence In Situ Hybridization Results. Am J Clin Pathol. 2021 Oct 13; 156 (5):886-894
    View PubMed
  6. Chen B, Erickson LA. Metaplastic Breast Cancer. Mayo Clin Proc. 2021 Sep; 96 (9):2498-2499
    View PubMed
  7. Haddad TC, He J, O'Sullivan CC, Chen B, Northfelt D, Dueck AC, Ballman KV, Tenner KS, Linden H, Sparano JA, Hopkins JO, De Silva C, Perez EA, Haluska P, Goetz MP. Randomized Phase II Trial of Capecitabine and Lapatinib with or without IMC-A12 (Cituxumumab) in Patients with HER2-Positive Advanced Breast Cancer Previously Treated with Trastuzumab and Chemotherapy: NCCTG N0733 (Alliance). Breast Cancer Res Treat. 2021 Jul; 188 (2):477-487 Epub 2021 Apr 14
    View PubMed
  8. Geiersbach KB, Sill DR, Meyer RG, Yuhas JA, Sukov WR, Mounajjed T, Carter JM, Jenkins RB, Chen B. HER2 Testing for Breast Cancer in the Genomics Laboratory: A Sea Change for Fluorescence In Situ Hybridization. Arch Pathol Lab Med. 2021 Jul 1; 145 (7):883-886
    View PubMed
  9. Chen B, Erickson LA. Juvenile Papillomatosis of Breast. Mayo Clin Proc. 2021 Apr; 96 (4):1097-1098
    View PubMed
  10. Erickson LA, Chen B. Papillary Thyroid Carcinoma BRAF Immunopositivity. Mayo Clin Proc. 2021 Jan; 96 (1):267-268
    View PubMed
  11. Erickson LA, Chen B. Fibroadenoma of the Breast. Mayo Clin Proc. 2020 Nov; 95 (11):2573-2574
    View PubMed
  12. Yee D, DeMichele AM, Yau C, Isaacs C, Symmans WF, Albain KS, Chen YY, Krings G, Wei S, Harada S, Datnow B, Fadare O, Klein M, Pambuccian S, Chen B, Adamson K, Sams S, Mhawech-Fauceglia P, Magliocco A, Feldman M, Rendi M, Sattar H, Zeck J, Ocal IT, Tawfik O, LeBeau LG, Sahoo S, Vinh T, Chien AJ, Forero-Torres A, Stringer-Reasor E, Wallace AM, Pusztai L, Boughey JC, Ellis ED, Elias AD, Lu J, Lang JE, Han HS, Clark AS, Nanda R, Northfelt DW, Khan QJ, Viscusi RK, Euhus DM, Edmiston KK, Chui SY, Kemmer K, Park JW, Liu MC, Olopade O, Leyland-Jones B, Tripathy D, Moulder SL, Rugo HS, Schwab R, Lo S, Helsten T, Beckwith H, Haugen P, Hylton NM, Van't Veer LJ, Perlmutter J, Melisko ME, Wilson A, Peterson G, Asare AL, Buxton MB, Paoloni M, Clennell JL, Hirst GL, Singhrao R, Steeg K, Matthews JB, Asare SM, Sanil A, Berry SM, Esserman LJ, Berry DA, I-SPY2 Trial Consortium. Association of Event-Free and Distant Recurrence-Free Survival With Individual-Level Pathologic Complete Response in Neoadjuvant Treatment of Stages 2 and 3 Breast Cancer: Three-Year Follow-up Analysis for the I-SPY2 Adaptively Randomized Clinical Trial. JAMA Oncol. 2020 Sep 1; 6 (9):1355-1362
    View PubMed
  13. Guo R, Chen B, Erickson LA. Mucinous Carcinoma of the Breast. Mayo Clin Proc. 2020 Sep; 95 (9):2049-2050
    View PubMed
  14. Leon-Ferre RA, Perez EA, Hillman DW, Bueno C, Perez AT, Chen B, Jenkins RB, Northfelt DW, Johnson DB, Carolla RL, Zon RT, Moreno-Aspitia A. N083E (Alliance): long-term outcomes of patients treated in a pilot phase II study of docetaxel, carboplatin, trastuzumab, and lapatinib as adjuvant therapy for early-stage HER2-positive breast cancer. Breast Cancer Res Treat. 2020 Aug; 182 (3):613-622 Epub 2020 June 05
    View PubMed
  15. Geiersbach KB, Meyer RG, Sill DR, Mounajjed T, Chen B, Sukov WR, Jenkins RB. Working Up Group 4 Equivocal HER2 Samples Tested by Fluorescence in Situ Hybridization in a Reference Laboratory Setting: Past, Present, and Future. J Clin Oncol. 2020 Jan 10; 38(2):175-176. Epub 2019 Nov 26.
    View PubMed
  16. Harrison BT, Fowler E, Krings G, Chen YY, Bean GR, Vincent-Salomon A, Fuhrmann L, Barnick SE, Chen B, Hosfield EM, Hornick JL, Schnitt SJ. Pan-TRK Immunohistochemistry: A Useful Diagnostic Adjunct For Secretory Carcinoma of the Breast. Am J Surg Pathol. 2019 Dec; 43 (12):1693-1700
    View PubMed
  17. Murphy BL, Gonzalez AB, Keeney MG, Chen B, Conners AL, Henrichsen TL, Degnim AC, Harmsen WS, Boughey JC, Hieken TJ, Habermann EB, Jakub JW. Ability of Intraoperative Pathologic Analysis of Ductal Carcinoma In Situ to Guide Selective Use of Sentinel Lymph Node Surgery. Am Surg. 2018 Apr 1; 84 (4):537-542
    View PubMed
  18. Haskell GT, Liu YJ, Chen H, Chen B, Meyer RG, Yuhas JA, Geiersbach KB. Integrated Analysis of HER2 Copy Number by Cytogenomic Microarray in Breast Cancers With Nonclassical In Situ Hybridization Results. Am J Clin Pathol. 2018 Jan 29; 149 (2):135-147
    View PubMed
  19. Jakub JW, Murphy BL, Gonzalez AB, Conners AL, Henrichsen TL, Maimone S 4th, Keeney MG, McLaughlin SA, Pockaj BA, Chen B, Musonza T, Harmsen WS, Boughey JC, Hieken TJ, Habermann EB, Shah HN, Degnim AC. A Validated Nomogram to Predict Upstaging of Ductal Carcinoma in Situ to Invasive Disease. Ann Surg Oncol. 2017 Oct; 24 (10):2915-2924 Epub 2017 Aug 01
    View PubMed
  20. Olsen DL, Keeney GL, Chen B, Visscher DW, Carter JM. Breast implant capsule-associated squamous cell carcinoma: a report of 2 cases. Hum Pathol. 2017 Sep; 67:94-100 Epub 2017 July 22
    View PubMed
  21. Reinholz MM, Chen B, Dueck AC, Tenner K, Ballman K, Riehle D, Jenkins RB, Geiger XJ, McCullough AE, Perez EA. IGF1R Protein Expression Is Not Associated with Differential Benefit to Concurrent Trastuzumab in Early-Stage HER2(+) Breast Cancer from the North Central Cancer Treatment Group (Alliance) Adjuvant Trastuzumab Trial N9831. Clin Cancer Res. 2017 Aug 1; 23 (15):4203-4211 Epub 2017 May 22
    View PubMed
  22. Murphy BL, Gonzalez AB, Conners AL, Henrichsen TL, Keeney MG, Chen B, Nguyen TT, Harmsen WS, Habermann EB, Shah HN, Jakub JW. Identifying a subset of patients with DCIS who have a low likelihood of residual disease at surgical excision following a core needle biopsy. J Surg Oncol. 2017 Aug; 116 (2):213-219 Epub 2017 Apr 18
    View PubMed
  23. Peng Y, Butt YM, Chen B, Zhang X, Tang P. Update on Immunohistochemical Analysis in Breast Lesions. Arch Pathol Lab Med. 2017 Aug; 141 (8):1033-1051 Epub 2017 June 02
    View PubMed
  24. Lopez JJ, Chen B, Ghosh K, Peters MS. Low-Grade Malignant Proliferating Tricholemmal Tumor Associated With Occult Ductal Carcinoma In Situ of the Breast. Am J Dermatopathol. 2016 Oct; 38: (10)e144-6.
    View PubMed
  25. Perez EA, Thompson EA, Ballman KV, Anderson SK, Asmann YW, Kalari KR, Eckel-Passow JE, Dueck AC, Tenner KS, Jen J, Fan JB, Geiger XJ, McCullough AE, Chen B, Jenkins RB, Sledge GW, Winer EP, Gralow JR, Reinholz MM. Genomic analysis reveals that immune function genes are strongly linked to clinical outcome in the North Central Cancer Treatment Group n9831 Adjuvant Trastuzumab Trial. J Clin Oncol. 2015 Mar 1; 33 (7):701-8 Epub 2015 Jan 20
    View PubMed
  26. Fatemi Y, Hurley R, Grant C, Henrichsen T, Chen B, Ghosh K. Challenges in the management of giant intraductal breast papilloma. Clin Case Rep. 2015 Jan; 3 (1):7-10 Epub 2014 Nov 25
    View PubMed
  27. Cheng H, Ballman K, Vassilakopoulou M, Dueck AC, Reinholz MM, Tenner K, Gralow J, Hudis C, Davidson NE, Fountzilas G, McCullough AE, Chen B, Psyrri A, Rimm DL, Perez EA. EGFR expression is associated with decreased benefit from trastuzumab in the NCCTG N9831 (Alliance) trial. Br J Cancer. 2014 Sep 9; 111 (6):1065-71 Epub 2014 Aug 12
    View PubMed
  28. McCullough AE, Dell'orto P, Reinholz MM, Gelber RD, Dueck AC, Russo L, Jenkins RB, Andrighetto S, Chen B, Jackisch C, Untch M, Perez EA, Piccart-Gebhart MJ, Viale G. Central pathology laboratory review of HER2 and ER in early breast cancer: an ALTTO trial [BIG 2-06/NCCTG N063D (Alliance)] ring study. Breast Cancer Res Treat. 2014 Feb; 143 (3):485-92 Epub 2014 Jan 07
    View PubMed
  29. Dueck AC, Reinholz MM, Geiger XJ, Tenner K, Ballman K, Jenkins RB, Riehle D, Chen B, McCullough AE, Davidson NE, Martino S, Sledge GW, Kaufman PA, Kutteh LA, Gralow J, Harris LN, Ingle JN, Lingle WL, Perez EA. Impact of c-MYC protein expression on outcome of patients with early-stage HER2+ breast cancer treated with adjuvant trastuzumab NCCTG (alliance) N9831. Clin Cancer Res. 2013 Oct 15; 19 (20):5798-807 Epub 2013 Aug 21
    View PubMed
  30. Perez EA, Dueck AC, McCullough AE, Chen B, Geiger XJ, Jenkins RB, Lingle WL, Davidson NE, Martino S, Kaufman PA, Kutteh LA, Sledge GW, Harris LN, Gralow JR, Reinholz MM. Impact of PTEN protein expression on benefit from adjuvant trastuzumab in early-stage human epidermal growth factor receptor 2-positive breast cancer in the North Central Cancer Treatment Group N9831 trial. J Clin Oncol. 2013 Jun 10; 31 (17):2115-22 Epub 2013 May 06
    View PubMed
  31. Said SM, Reynolds C, Jimenez RE, Chen B, Vrana JA, Theis JD, Dogan A, Shah SS. Amyloidosis of the breast: predominantly AL type and over half have concurrent breast hematologic disorders. Mod Pathol. 2013 Feb; 26(2):232-8. Epub 2012 Sep 28.
    View PubMed
  32. Perez EA, Press MF, Dueck AC, Jenkins RB, Kim C, Chen B, Villalobos I, Paik S, Buyse M, Wiktor AE, Meyer R, Finnigan M, Zujewski J, Shing M, Stern HM, Lingle WL, Reinholz MM, Slamon DJ. Immunohistochemistry and fluorescence in situ hybridization assessment of HER2 in clinical trials of adjuvant therapy for breast cancer (NCCTG N9831, BCIRG 006, and BCIRG 005). Breast Cancer Res Treat. 2013 Feb; 138 (1):99-108 Epub 2013 Feb 19
    View PubMed
  33. Sciallis AP, Chen B, Folpe AL. Cellular spindled histiocytic pseudotumor complicating mammary fat necrosis: a potential diagnostic pitfall. Am J Surg Pathol. 2012 Oct; 36(10):1571-8.
    View PubMed
  34. Wahner-Roedler DL, Boughey JC, Hruska CB, Chen B, Rhodes DJ, Tortorelli CL, Maxwell RW, Cha SS, O'Connor MK. The use of molecular breast imaging to assess response in women undergoing neoadjuvant therapy for breast cancer: a pilot study. Clin Nucl Med. 2012 Apr; 37(4):344-50.
    View PubMed
  35. Minot DM, Voss J, Rademacher S, Lwin T, Orsulak J, Caron B, Ketterling R, Nassar A, Chen B, Clayton A. Image analysis of HER2 immunohistochemical staining. Reproducibility and concordance with fluorescence in situ hybridization of a laboratory-validated scoring technique. Am J Clin Pathol. 2012 Feb; 137 (2):270-6
    View PubMed
  36. Perez EA, Dueck AC, McCullough AE, Reinholz MM, Tenner KS, Davidson NE, Gralow J, Harris LN, Kutteh LA, Hillman DW, Jenkins RB, Chen B. Predictability of adjuvant trastuzumab benefit in N9831 patients using the ASCO/CAP HER2-positivity criteria. J Natl Cancer Inst. 2012 Jan 18; 104 (2):159-62 Epub 2011 Dec 02
    View PubMed
  37. Strizzi L, Hardy KM, Margaryan NV, Hillman DW, Seftor EA, Chen B, Geiger XJ, Thompson EA, Lingle WL, Andorfer CA, Perez EA, Hendrix MJ. Potential for the embryonic morphogen Nodal as a prognostic and predictive biomarker in breast cancer. Breast Cancer Res. 2012; 14(3):R75. Epub 2012 May 11.
    View PubMed
  38. Perez EA, Suman VJ, Davidson NE, Gralow JR, Kaufman PA, Visscher DW, Chen B, Ingle JN, Dakhil SR, Zujewski J, Moreno-Aspitia A, Pisansky TM, Jenkins RB. Sequential versus concurrent trastuzumab in adjuvant chemotherapy for breast cancer. J Clin Oncol. 2011 Dec 1; 29 (34):4491-7 Epub 2011 Oct 31
    View PubMed
  39. Rimm DL, Nielsen TO, Jewell SD, Rohrer DC, Broadwater G, Waldman F, Mitchell KA, Singh B, Tsongalis GJ, Frankel WL, Magliocco AM, Lara JF, Hsi ED, Bleiweiss IJ, Badve SS, Chen B, Ravdin PM, Schilsky RL, Thor A, Berry DA, Cancer and. Cancer and Leukemia Group B Pathology Committee guidelines for tissue microarray construction representing multicenter prospective clinical trial tissues. J Clin Oncol. 2011 Jun 1; 29(16):2282-90. Epub 2011 Apr 25.
    View PubMed
  40. Perez EA, Jenkins RB, Dueck AC, Wiktor AE, Bedroske PP, Anderson SK, Ketterling RP, Sukov WR, Kanehira K, Chen B, Geiger XJ, Andorfer CA, McCullough AE, Davidson NE, Martino S, Sledge GW, Kaufman PA, Kutteh LA, Gralow JR, Harris LN, Ingle JN, Lingle WL, Reinholz MM. C-MYC alterations and association with patient outcome in early-stage HER2-positive breast cancer from the north central cancer treatment group N9831 adjuvant trastuzumab trial. J Clin Oncol. 2011 Feb 20; 29 (6):651-9 Epub 2011 Jan 18
    View PubMed
  41. Thanarajasingam U, Chen B, Tortorelli CL, Jakub JW, Ghosh K. Diabetic mastopathy as a radiographically occult palpable breast mass. Case Rep Med. 2011; 2011:162350 Epub 2011 Nov 03
    View PubMed
  42. Reinholz MM, Eckel-Passow JE, Anderson SK, Asmann YW, Zschunke MA, Oberg AL, McCullough AE, Dueck AC, Chen B, April CS, Wickham-Garcia E, Jenkins RB, Cunningham JM, Jen J, Perez EA, Fan JB, Lingle WL. Expression profiling of formalin-fixed paraffin-embedded primary breast tumors using cancer-specific and whole genome gene panels on the DASL(R) platform. BMC Med Genomics. 2010 Dec 20; 3:60
    View PubMed
  43. Shah S, Chen B. Testing for HER2 in Breast Cancer: A Continuing Evolution. Patholog Res Int. 2010 Dec 6; 2011:903202 Epub 2010 Dec 06
    View PubMed
  44. Huang W, Reinholz M, Weidler J, Yolanda L, Paquet A, Whitcomb J, Lingle W, Jenkins RB, Chen B, Larson JS, Tan Y, Sherwood T, Bates M, Perez EA. Comparison of central HER2 testing with quantitative total HER2 expression and HER2 homodimer measurements using a novel proximity-based assay. Am J Clin Pathol. 2010 Aug; 134(2):303-11.
    View PubMed
  45. Shah SS, Ketterling RP, Goetz MP, Ingle JN, Reynolds CA, Perez EA, Chen B. Impact of American Society of Clinical Oncology/College of American Pathologists guideline recommendations on HER2 interpretation in breast cancer. Hum Pathol. 2010 Jan; 41(1):103-6. Epub 2009 Sep 16
    View PubMed
  46. Vijan SS, Hamilton S, Chen B, Reynolds C, Boughey JC, Degnim AC. Intramammary lymph nodes: patterns of discovery and clinical significance. Surgery. 2009 May; 145(5):495-9. Epub 2009 Mar 29.
    View PubMed
  47. Shin SJ, Chen B, Hyjek E, Vazquez M. Immunocytochemistry and fluorescence in situ hybridization in HER-2/neu status in cell block preparations. Acta Cytol. 2007 Jul-Aug; 51(4):552-7.
    View PubMed
  48. Bhargava R, Chen B, Klimstra DS, Saltz LB, Hedvat C, Tang LH, Gerald W, Teruya-Feldstein J, Paty PB, Qin J, Shia J. Comparison of two antibodies for immunohistochemical evaluation of epidermal growth factor receptor expression in colorectal carcinomas, adenomas, and normal mucosa. Cancer. 2006 Apr 15; 106(8):1857-62.
    View PubMed
  49. Arocho A, Chen B, Ladanyi M, Pan Q. Validation of the 2-DeltaDeltaCt calculation as an alternate method of data analysis for quantitative PCR of BCR-ABL P210 transcripts. Diagn Mol Pathol. 2006 Mar; 15(1):56-61.
    View PubMed
  50. Shia J, Klimstra DS, Li AR, Qin J, Saltz L, Teruya-Feldstein J, Akram M, Chung KY, Yao D, Paty PB, Gerald W, Chen B. Epidermal growth factor receptor expression and gene amplification in colorectal carcinoma: an immunohistochemical and chromogenic in situ hybridization study. Mod Pathol. 2005 Oct; 18(10):1350-6.
    View PubMed
  51. Bhargava R, Gerald WL, Li AR, Pan Q, Lal P, Ladanyi M, Chen B. EGFR gene amplification in breast cancer: correlation with epidermal growth factor receptor mRNA and protein expression and HER-2 status and absence of EGFR-activating mutations. Mod Pathol. 2005 Aug; 18(8):1027-33.
    View PubMed
  52. Bhargava R, Oppenheimer O, Gerald W, Jhanwar SC, Chen B. Identification of MYCN gene amplification in neuroblastoma using chromogenic in situ hybridization (CISH): an alternative and practical method. Diagn Mol Pathol. 2005 Jun; 14(2):72-6.
    View PubMed
  53. Bhargava R, Lal P, Chen B. HER-2/neu and topoisomerase IIa gene amplification and protein expression in invasive breast carcinomas: chromogenic in situ hybridization and immunohistochemical analyses. Am J Clin Pathol. 2005 Jun; 123(6):889-95.
    View PubMed
  54. Lal P, Tan LK, Chen B. Correlation of HER-2 status with estrogen and progesterone receptors and histologic features in 3,655 invasive breast carcinomas. Am J Clin Pathol. 2005 Apr; 123(4):541-6.
    View PubMed
  55. Bhargava R, Lal P, Chen B. Chromogenic in situ hybridization for the detection of HER-2/neu gene amplification in breast cancer with an emphasis on tumors with borderline and low-level amplification: does it measure up to fluorescence in situ hybridization? Am J Clin Pathol. 2005 Feb; 123(2):237-43.
    View PubMed
  56. Wu Y, Soslow RA, Marshall DS, Leitao M, Chen B. Her-2/neu expression and amplification in early stage ovarian surface epithelial neoplasms. Gynecol Oncol. 2004 Dec; 95(3):570-5.
    View PubMed
  57. Bhargava R, Lal P, Chen B. Feasibility of using tissue microarrays for the assessment of HER-2 gene amplification by fluorescence in situ hybridization in breast carcinoma. Diagn Mol Pathol. 2004 Dec; 13(4):213-6.
    View PubMed
  58. Lal P, Salazar PA, Hudis CA, Ladanyi M, Chen B. HER-2 testing in breast cancer using immunohistochemical analysis and fluorescence in situ hybridization: a single-institution experience of 2,279 cases and comparison of dual-color and single-color scoring. Am J Clin Pathol. 2004 May; 121(5):631-6.
    View PubMed
  59. Chen B, Colleoni GW, Salazar PA, Lal P, Gerdes H, Filippa DA. Molecular analysis of gastric washings in the diagnosis and monitoring of gastric lymphomas. Hum Pathol. 2004 May; 35(5):582-6.
    View PubMed
  60. Nathanson DR, Nash GM, Chen B, Gerald W, Paty PB. Detection of HER-2/neu gene amplification in breast cancer using a novel polymerase chain reaction/ligase detection reaction technique. J Am Coll Surg. 2003 Sep; 197(3):419-25.
    View PubMed
  61. Lal P, Salazar PA, Ladanyi M, Chen B. Impact of polysomy 17 on HER-2/neu immunohistochemistry in breast carcinomas without HER-2/neu gene amplification. J Mol Diagn. 2003 Aug; 5(3):155-9.
    View PubMed
  62. Nathanson DR, Culliford AT 4th, Shia J, Chen B, D'Alessio M, Zeng ZS, Nash GM, Gerald W, Barany F, Paty PB. HER 2/neu expression and gene amplification in colon cancer. Int J Cancer. 2003 Jul 20; 105(6):796-802.
    View PubMed
  63. Hedvat CV, Hegde A, Chaganti RS, Chen B, Qin J, Filippa DA, Nimer SD, Teruya-Feldstein J. Application of tissue microarray technology to the study of non-Hodgkin's and Hodgkin's lymphoma. Hum Pathol. 2002 Oct; 33(10):968-74.
    View PubMed
  64. Chen B, Marshall DS, Hedvat CV, Soslow RA. Her-2/neu (c-erb-B2) in endometrial carcinoma. Histopathol. 2002; 41(suppl 1):82.
  65. Kaptain S, Tan LK, Chen B. Her-2/neu and breast cancer. Diagn Mol Pathol. 2001 Sep; 10(3):139-52.
    View PubMed
  66. Chen B, Jhanwar SC, Ladanyi M. Rearrangement in the coding region of the MYCN gene in a subset of amplicons in a case of neuroblastoma with MYCN amplification. Diagn Mol Pathol. 2001 Jun; 10(2):100-4.
    View PubMed
  67. Colleoni GW, Jhanwar SC, Ladanyi M, Chen B. Comparison of a multiplex reverse transcriptase-polymerase chain reaction for BCR-ABL to fluorescence in situ hybridization, Southern blotting, and conventional cytogenetics in the monitoring of patients with Ph1-positive leukemias. Diagn Mol Pathol. 2000 Dec; 9(4):203-9.
    View PubMed
  68. Chen B, Hales BF. Antisense oligonucleotide down-regulation of E-cadherin in the yolk sac and cranial neural tube malformations. Biol Reprod. 1995 Nov; 53(5):1229-38.
    View PubMed
  69. Chen B, Hales BF. 12-O-tetradecanoyl-phorbol-13-acetate-induced rat embryo malformations in vitro are associated with an increased relative abundance of embryonic E-cadherin mRNA. Teratology. 1994 Oct; 50(4):302-10.
    View PubMed
  70. Chen B, Hales BF. Cadmium-induced rat embryotoxicity in vitro is associated with an increased abundance of E-cadherin protein in the yolk sac. Toxicol Appl Pharmacol. 1994 Oct; 128(2):293-301.
    View PubMed
  71. Mobley PL, Hedberg K, Bonin L, Chen B, Griffith OH. Decreased phosphorylation of four 20-kDa proteins precedes staurosporine-induced disruption of the actin/myosin cytoskeleton in rat astrocytes. Exp Cell Res. 1994 Sep; 214(1):55-66.
    View PubMed
  72. Chen B, Cyr DG, Hales BF. Role of apoptosis in mediating phosphoramide mustard-induced rat embryo malformations in vitro. Teratology. 1994 Jul; 50(1):1-12.
    View PubMed
  73. Chen B, Blaschuk OW, Hales BF. Cadherin mRNAs during rat embryo development in vivo and in vitro. Teratology. 1991 Nov; 44(5):581-90.
    View PubMed